SYK-69 | 1256921-88-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: SYK-69
• 英文别名: (1R,14S,15R)-25-(cyclopentylmethyl)-4,25-diazahexacyclo[13.7.3.01,14.03,12.05,10.017,22]pentacosa-3,5,7,9,11,17(22),18,20-octaene-14,20-diol
• CAS: 1256921-88-6
• 化学式: C₂₉H₃₂N₂O₂
• 分子量: 440.585
• InChiKey: QWTULUQEUAAAGP-MPFGFTFXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  33
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  56.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (6R,6aS,14aR)-17-(cyclopentylmethyl)-2-methoxy-5,6,7,14-tetrahydro-6aH-6,14a-(epiminoethano)naphtho[2,1-b]acridin-6a-ol 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以70%的产率得到SYK-69
  参考文献：
  名称：

  Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration

  摘要：

  We have reported previously the novel delta-opioid agonist, SN-28, which was more potent in in vitro assays than the prototype delta-agonists, TAN-67 and SNC-80. However, when administered by subcutaneous injection, this compound showed no analgesic effect at dosages greater than 30 mg/kg in the acetic acid writhing test. We speculated that SN-28 was not effective in the test because the presence of the charged ammonium groups prevented its penetration through the blood-brain barrier. On the basis of our proposal, we designed the novel delta-agonist, KNT-127, which was effective with systemic administration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.083

文献信息

• Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration
  作者：Hiroshi Nagase、Toru Nemoto、Ayaka Matsubara、Manabu Saito、Naoshi Yamamoto、Yumiko Osa、Shigeto Hirayama、Mayumi Nakajima、Kaoru Nakao、Hidenori Mochizuki、Hideaki Fujii

  DOI：10.1016/j.bmcl.2010.08.083

  日期：2010.11

  We have reported previously the novel delta-opioid agonist, SN-28, which was more potent in in vitro assays than the prototype delta-agonists, TAN-67 and SNC-80. However, when administered by subcutaneous injection, this compound showed no analgesic effect at dosages greater than 30 mg/kg in the acetic acid writhing test. We speculated that SN-28 was not effective in the test because the presence of the charged ammonium groups prevented its penetration through the blood-brain barrier. On the basis of our proposal, we designed the novel delta-agonist, KNT-127, which was effective with systemic administration. (C) 2010 Elsevier Ltd. All rights reserved.